BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34331021)

  • 21. CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy.
    Isshiki Y; Ohwada C; Sakaida E; Onoda M; Aotsuka N; Tanaka H; Fukazawa M; Cho R; Sugawara T; Kawaguchi T; Hara S; Yokota A
    Jpn J Clin Oncol; 2017 Nov; 47(11):1047-1054. PubMed ID: 28973362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic analysis of allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in complete remission in the era of tyrosine kinase inhibitors].
    Cao XY; Ma W; Zhang W; Liu DY; Zhao YL; Lu Y; Zhang JP; Zhou JR; Xiong M; Wei ZJ; Sun RJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):564-569. PubMed ID: 32810963
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.
    Chang J; Douer D; Aldoss I; Vahdani G; Jeong AR; Ghaznavi Z; Zhang S; Yaghmour G; Lee KJ; Weissman A; Akhtari M
    Cancer Med; 2019 Jun; 8(6):2832-2839. PubMed ID: 31016870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparable outcomes of partially matched related and matched related allogeneic hematopoietic cell transplantation following reduced-intensity conditioning in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Wu X; He G; Fa Y; Ma X; Wu D; Ai H; Huang X; Han Y; Xu Y; Sun A; Wu Q; Tang X; Fu Z
    Int J Hematol; 2013 Oct; 98(4):456-62. PubMed ID: 23975518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamics of minimal residual disease defines a novel risk-classification and the role of allo-HSCT in adult Ph-negative B-cell acute lymphoblastic leukemia.
    Cai Z; Liu Y; Tang B; Wu Z; Wang Z; Lin R; Xu X; Huang Z; Ou J; Li X; Liu X; Liu Q; Zhou H
    Leuk Lymphoma; 2022 Dec; 63(13):3181-3190. PubMed ID: 36098226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
    Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation.
    Li Z; Lai Y; Zhang X; Xu L; Liu K; Wang Y; Yan C; Jiang H; Huang X; Jiang Q
    Ann Hematol; 2020 Aug; 99(8):1833-1843. PubMed ID: 32577842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.
    Nishiwaki S; Akahoshi Y; Mizuta S; Shinohara A; Hirabayashi S; Noguchi Y; Fukuda T; Uchida N; Tanaka M; Onizuka M; Ozawa Y; Ota S; Shiratori S; Onishi Y; Kanda Y; Sawa M; Tanaka J; Atsuta Y; Kako S
    Blood Adv; 2021 Jan; 5(2):584-592. PubMed ID: 33496752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
    Czyz A; Lewandowski K; Kroll R; Komarnicki M
    Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The prognostic significance of minimal residual disease detection after first induction treatment in adult acute lymphoblastic leukemia patients treated with autologous stem cell transplantation].
    Huang ZF; Xu J; Fu MW; Wang TY; Hao M; Liu W; Qiu LG; Zou DH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):105-110. PubMed ID: 30831624
    [No Abstract]   [Full Text] [Related]  

  • 32. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.
    Combariza JF; Arango M; Díaz L; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Orduz R; Mejía F; Moreno L; Ramirez C
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e365-e372. PubMed ID: 33277225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XY; Han W; Zhang XH; Wang Y; Zhang YY; Qin YZ; Liu YR; Huang XJ
    J Hematol Oncol; 2012 Jun; 5():29. PubMed ID: 22682059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
    Ribera JM; Morgades M; Ciudad J; Montesinos P; Esteve J; Genescà E; Barba P; Ribera J; García-Cadenas I; Moreno MJ; Martínez-Carballeira D; Torrent A; Martínez-Sánchez P; Monsalvo S; Gil C; Tormo M; Artola MT; Cervera M; González-Campos J; Rodríguez C; Bermúdez A; Novo A; Soria B; Coll R; Amigo ML; López-Martínez A; Fernández-Martín R; Serrano J; Mercadal S; Cladera A; Giménez-Conca A; Peñarrubia MJ; Abella E; Vall-Llovera F; Hernández-Rivas JM; Garcia-Guiñon A; Bergua JM; de Rueda B; Sánchez-Sánchez MJ; Serrano A; Calbacho M; Alonso N; Méndez-Sánchez JÁ; García-Boyero R; Olivares M; Barrena S; Zamora L; Granada I; Lhermitte L; Feliu E; Orfao A
    Blood; 2021 Apr; 137(14):1879-1894. PubMed ID: 33150388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A retrospective comparative study of haplotype hematopoietic stem cell transplantation and human leukocyte antigen-matched sibling donor hematopoietic stem cell transplantation in the treatment of acute B-lymphocyte leukemia].
    Wang ZD; Sun YQ; Yan CH; Wang FR; Mo XD; Lyu M; Zhao XS; Han W; Chen H; Chen YY; Wang Y; Xu LP; Wang YZ; Liu YR; Cheng YF; Zhang XH; Liu KY; Huang XJ; Chang YJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):221-228. PubMed ID: 35405780
    [No Abstract]   [Full Text] [Related]  

  • 38. Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission.
    Kaito S; Kurosawa S; Najima Y; Sakaida E; Shingai N; Fukuda T; Tachibana T; Uchida N; Ozawa Y; Sawa M; Nakazawa H; Ota S; Kato J; Nakamae H; Katayama Y; Eto T; Tanaka J; Kanda Y; Atsuta Y; Arai Y; Kako S;
    Transplant Cell Ther; 2022 Jun; 28(6):326.e1-326.e10. PubMed ID: 35306218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 40. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.